Analysis of the current state of the pharmaceutical market of the Republic of Kazakhstan

Q3 Pharmacology, Toxicology and Pharmaceutics

ScienceRise: Pharmaceutical Science Pub Date : 2023-04-30 DOI:10.15587/2519-4852.2023.267787

K. Zhakipbekov, O. Posylkina, Narbek Zhumabayev, U. Datkhayev, N. Zhumabayev, Almira Almurzaeva, Arailym Mukanova

{"title":"Analysis of the current state of the pharmaceutical market of the Republic of Kazakhstan","authors":"K. Zhakipbekov, O. Posylkina, Narbek Zhumabayev, U. Datkhayev, N. Zhumabayev, Almira Almurzaeva, Arailym Mukanova","doi":"10.15587/2519-4852.2023.267787","DOIUrl":null,"url":null,"abstract":"This article analyses the current state of the pharmaceutical market of the Republic of Kazakhstan for the period 2015-2021 and diagnoses the current problems of pharmaceutical production.\nThe aim: to identify the current trends of the pharmaceutical market in the Republic of Kazakhstan, its specific features and prospects for the development of domestic pharmaceutical production.\nMaterials and methods: statistical data, survey results, mathematical-statistical and analytical comparative methods, SWOT analysis.\nResearch results: according to the results of statistical analysis, pharmaceutical production increased by 101.1 billion tenges in monetary terms compared to 2015, and the export of domestic products increased by 13.3 billion tenges. In 2020, the export of medical preparations due to supplies to Russia amounted to 76.5 %, to Kyrgyzstan 6.5 % and Uzbekistan 4.8 %, to other countries - 12.3 %. It is estimated that the volume of the pharmaceutical market of the Republic of Kazakhstan in 2020, compared with 2019, increased by 21.3 % as a result of the development of domestic production and the implementation of the state support program. The total number of medicines registered in the republic is 7449, and the share of domestic production is 13.1 % (978 medical preparations), and 6471 medicines, 86.9 %, are imported. In addition, 9154 medical devices have been registered, and the share of domestic products is 90 %.\nOnline direct expert survey (questionnaire) indicates that the respondents are female pharmacists (74.5 %) aged 36 to 55 years old (52.3 %) with 26-30 years of work experience (32.3 %), who noted the strengths of the development of the pharmaceutical industry in Kazakhstan (U=1.35), as readiness for modernisation and state support (47 %), political stability (44 %), weaknesses (U=1.35) - insignificant capacity of the pharmaceutical market (55.5 %), limited range of domestic pharmaceutical products and substances (50.9 %), opportunities (U=1.4) - active investment policy (62.7 %), expansion of digital and remote channels (25.4 %), threats (U=1.4) – import dependence (69.9 %), high volatility of the tenge exchange rate (24.1 %).\nBased on the pharmaceutical market analysis and expert survey of specialists, a strategic matrix of SWOT analysis was built.\nConclusion. As a result of the analysis, the dependence of the pharmaceutical industry and the pharmaceutical market on imported foreign medicines and substances were revealed. However, the volume of pharmaceutical products produced in the Republic of Kazakhstan increases annually. Therefore, for the further development of the pharmaceutical industry of the Republic of Kazakhstan, considering its import dependence, additional funding is needed for research and educational activities for the development of innovative medical preparations and substances","PeriodicalId":21674,"journal":{"name":"ScienceRise: Pharmaceutical Science","volume":"518 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ScienceRise: Pharmaceutical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15587/2519-4852.2023.267787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

This article analyses the current state of the pharmaceutical market of the Republic of Kazakhstan for the period 2015-2021 and diagnoses the current problems of pharmaceutical production. The aim: to identify the current trends of the pharmaceutical market in the Republic of Kazakhstan, its specific features and prospects for the development of domestic pharmaceutical production. Materials and methods: statistical data, survey results, mathematical-statistical and analytical comparative methods, SWOT analysis. Research results: according to the results of statistical analysis, pharmaceutical production increased by 101.1 billion tenges in monetary terms compared to 2015, and the export of domestic products increased by 13.3 billion tenges. In 2020, the export of medical preparations due to supplies to Russia amounted to 76.5 %, to Kyrgyzstan 6.5 % and Uzbekistan 4.8 %, to other countries - 12.3 %. It is estimated that the volume of the pharmaceutical market of the Republic of Kazakhstan in 2020, compared with 2019, increased by 21.3 % as a result of the development of domestic production and the implementation of the state support program. The total number of medicines registered in the republic is 7449, and the share of domestic production is 13.1 % (978 medical preparations), and 6471 medicines, 86.9 %, are imported. In addition, 9154 medical devices have been registered, and the share of domestic products is 90 %. Online direct expert survey (questionnaire) indicates that the respondents are female pharmacists (74.5 %) aged 36 to 55 years old (52.3 %) with 26-30 years of work experience (32.3 %), who noted the strengths of the development of the pharmaceutical industry in Kazakhstan (U=1.35), as readiness for modernisation and state support (47 %), political stability (44 %), weaknesses (U=1.35) - insignificant capacity of the pharmaceutical market (55.5 %), limited range of domestic pharmaceutical products and substances (50.9 %), opportunities (U=1.4) - active investment policy (62.7 %), expansion of digital and remote channels (25.4 %), threats (U=1.4) – import dependence (69.9 %), high volatility of the tenge exchange rate (24.1 %). Based on the pharmaceutical market analysis and expert survey of specialists, a strategic matrix of SWOT analysis was built. Conclusion. As a result of the analysis, the dependence of the pharmaceutical industry and the pharmaceutical market on imported foreign medicines and substances were revealed. However, the volume of pharmaceutical products produced in the Republic of Kazakhstan increases annually. Therefore, for the further development of the pharmaceutical industry of the Republic of Kazakhstan, considering its import dependence, additional funding is needed for research and educational activities for the development of innovative medical preparations and substances

查看原文本刊更多论文

哈萨克斯坦共和国医药市场现状分析

本文分析了哈萨克斯坦共和国2015-2021年期间药品市场的现状，并诊断了当前药品生产的问题。目的:确定哈萨克斯坦共和国药品市场的当前趋势，其具体特点和国内药品生产发展的前景。资料与方法:统计数据、调查结果、数理统计与分析比较法、SWOT分析法。研究结果:根据统计分析结果，药品产量较2015年货币增长1011亿坚戈，国内产品出口增长133亿坚戈。2020年，由于供应的医疗制剂出口到俄罗斯占76.5%，到吉尔吉斯斯坦占6.5%，到乌兹别克斯坦占4.8%，到其他国家占12.3%。据估计，由于国内生产的发展和国家支持计划的实施，2020年哈萨克斯坦共和国药品市场的数量与2019年相比增长了21.3%。在共和国登记的药品总数为7449种，国内生产的份额为13.1%(978种医药制剂)，进口的药品为6471种，占86.9%。注册医疗器械9154件，国产化份额达90%。在线直接专家调查(问卷)表明，受访者是36至55岁(52.3%)的女药剂师(74.5%)，具有26-30年的工作经验(32.3%)，他们注意到哈萨克斯坦制药工业发展的优势(U=1.35)，现代化准备和国家支持(47%)，政治稳定(44%)，弱点(U=1.35) -医药市场容量微不足道(55.5%)。国内医药产品和物质的范围有限(50.9%)，机会(U=1.4) -积极的投资政策(62.7%)，数字和远程渠道的扩张(25.4%)，威胁(U=1.4) -进口依赖(69.9%)，坚戈汇率的高度波动(24.1%)。在医药市场分析和专家调查的基础上，构建了SWOT分析的战略矩阵。分析结果揭示了我国制药业和医药市场对进口外国药品和物质的依赖程度。然而，哈萨克斯坦共和国生产的药品数量每年都在增加。因此，考虑到哈萨克斯坦共和国对进口的依赖，为了进一步发展其制药业，需要为研究和教育活动提供更多资金，以开发创新的医药制剂和物质

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊